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Four distinct FGF receptors were cloned and characterized and it was demonstrated that the ligand binding site of FGF receptors IS confined to 
the extracellular immunoglobulin-like (Ig)-domain 2 and 3. The Ig-domain 3 IS encoded by two separate exons: exon IIIa encodes the N-terminal 
half. and the C-terminal half IS encoded by either exon IIIb or 111~ m FGFRl and FGFRZ. whereas FGFR4 is devoid of exon IIIb. Alternative 
usage of exons IIIb and 111~ determine the ligand bmdmg specificity of the receptor. To analyze the arrangement of these exons in FGFR3 we 
cloned the genomic sequence between exon IIIa and IIIc of FGFR3 and identified an alternattve exon. correspondmg to exon IIIb of the FGFRl 
and FGFR2. The sequence of this exon shows Ig-domain hallmarks. 44% Identity wtth exon IIIb of other FGF receptors and 36% Identity with 
exon 111~ of FGFR3. Using this exon as a probe for mouse RNA as well as PCR analysis, demonstrated that exon IIIb encodes an authentic form 
of FGFR3 that is expressed in mouse embryo, mouse skin and mouse epidermal keratmocytes. The results demonstrate that the presence of 
alternative exons for Ig-domain 3 IS a general phenomena m FGFRl. 2 and 3, and represents a novel genetic mechamsm for the generation of 
receptor dtversity. 
FGF receptor; Alternative splicing; Ligand specificity 
1. INTRODUCTION 
Fibroblast growth factors (FGF) constitute a family 
of seven heparin-binding related polypeptides which are 
mitogenic for a wide variety of cells of epithelial, 
mesenchymal and neuronal origin and are important in 
early embryonal development (reviewed in [1,2]). FGFs 
act by binding and signal transduction through cell sur- 
face receptors. Four distinct FGF receptors (FGFRll 
4) were identified and cloned from various species, in- 
cluding Xenopus, chicken, mouse and human. The four 
FGFRs were shown to belong to the receptor tyrosine 
kinase family. They share a basic structure of an ex- 
tracellular ligand binding region consists of three immu- 
noglobulin (Ig)-like domains, and a cytoplasmic split 
tyrosine kinase domain which are connected by a single 
transmembrane region (reviewed in [3X5]). A unique 
feature of this family of receptors is the multitude of 
structural variants including two and three Ig-domain 
receptors [6.7] secreted soluble receptors [8.9] and vari- 
ants with truncated cytoplasmic domain [lo]. Most of 
these forms can be explained by alternative splicing 
leading to deletion or termination [3]. The complexity 
of different FGFRs is further increased by differential 
usage of two alternative exons, denoted exon Illb and 
Illc, which encode the C-terminal half of Ig-domain 3. 
It has been shown that in FGFR2 this alternative exon 
usage results in a marked change of the receptor binding 
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specificity [l l-l 31. Thus. FGFR2 and keratinocyte 
growth factor receptor (KGFR) are two receptors de- 
rived from the same gene by alternative usage of either 
exon IIIb (KGFR) or 111~ (FGFR21bek). This repre- 
sents a novel genetic mechanism for the generation of 
receptor diversity. The FGFR4 gene was shown to lack 
this gene arrangement of two alternative exons for Ig-3 
domain [ 141, and to contain only exon 111~ but FGFR-1 
was shown to possess both lllb and 111~ exons [13,15]. 
To further analyze the generality of this unique gene 
arrangement we searched for alternative exons encod- 
ing for Ig-domain 3 in FGFR3. Previously we cloned 
the flg-2 gene [16] which was identified later to be the 
mouse FGFR3 [16,17]. We report here that the FGFR3 
gene contains two alternative exons (Illb and 111~) for 
the C-terminal half of Ig-domain 3. We also report the 
cloning and sequence of exon Illb and its expression in 
mouse tissues. The implication for binding specificity of 
FGFR3 is discussed. 
2. MATERIALS AND METHODS 
2 1. DNA isolutmn. sequencing and PCR analym 
A BALB/c mouse genomic library m EMBL4 was screened with a 
170 bp PHI fragment dertved from FGFR3 (nucleotide) 957-1127. 
[16]). Positive plaques were isolated by three rounds of plating and 
probing. Ohgonucleottdes 1 (5’-CACACCGGCCCATCCTGCAGG) 
and 3 (5’-GAACCTCTAGCTCCTTGTCGG) derived from nucleo- 
tides 944963 and 11441164 of FGFR3 [16]. respectively, were used 
to amplify by PCR a 2 kbp fragment from positive phages. The 
isolated fragment was cloned in pBS (Bluescript) and sequenced by the 
automated DNA sequencer 373A (Applied Biosystem) using synthetic 
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ohgonucleotldes as primers and Tuq dyedeoxy terminator cycle se- 
quencing Kit accordmg to the manufacturer‘s instructions. Ohgonu- 
cleotidcs 3 (5’-AAGGTCCTCAAGTCCTGGATCAGTGAGAAT) 
and 4 (5’-GAGTATCACAGCTGCCA CC) were used to amphfy bq 
PCR a 0.4 kb fragment from mouse keratmocqtes cDNA. Oligonucle- 
otide 5 (5’.CGAAGATCTATCAGTTTCCATCAGCTCCTCCTCA- 
GCTGCTTGGGCCCGTG) Nhich IS located near the tranamem- 
brane region of FGFR3 (nucleotlde 1295) and extends to exon IIIb 
was used together with ohgonucleotide number 3 to amplify cDNA 
specific to exon IIIb from the above 0.4 kb PCR product Ohgonucle- 
otide 6 (5’-GGCGCTAACACCACCGAG) and ohgonucleotlde 7 (5’. 
TGGCAGCACCACCAGCCAC) were drrlved from FGFR3 se- 
quence corresponding to eson 111~ and used as a control on the same 
template (see Fig I). PCR was performed for 35 cqclea of 1.5 mm 
denaturation at 94°C. 2 min annealmg at 56-C’ and 3 min extension 
at 72-C. The amphfied DNA was extracted with phenol. preclpltated 
with ethanol and analyzed by agarose gel electrophoresls folloued bl 
Southern blotting and probmg with “P-labeled probes. 
33.2. RN.1 prtym~irlm urd u~ulw.\ 
Total RNA was extracted by the guamdme Isothlocyanate method 
[18] and subjected to cDNA prrparatlon by reserve transcriptase. For 
preparation of cDNA 5 mg of total RNA uas Incubated m 30 ~1 of 
reverse transcrlptasc buffer (50 mM Tns-HCI. pH 8.3. 1.5 mM DTT. 
IO mM MgCI,), 1 mM dNTP. I5 u of RNAsm and 5 u of AMV super 
reverse transcnptase (Molecular Genetic resources) for 1 h at 4Z7’C 
A portIon of this reaction (10%) was used for the PCR reaction 
Hybndxatlon to mtrocellulose filters was performed for 16 h at 4??“C 
in 6 x SSC. 2 x Denharts’ solution, 0.1 mg/ml salmon sperm DNA. 
40% formamlde and 0.1% SDS 
3. RESULTS 
In order to isolate a genomic clone containing exons 
encoding for the Ig-3 domain we used a 170 bp PstI 
fragment derived from mouse FGFR3 (previously de- 
noted flg-2 [16]) as a probe to screen a mouse gene 
library in EMBL4. This probe corresponds to eaon IIla, 
encoding the N-terminal half of Ig-domain 3. Some of 
the isolated clones were found to hybridize to the above 
probe as well as to a probe derived from exon 111~ of 
FGFR3. Amplification of the DNA between exons IIIa 
and 111~ by PCR, using primers 1 and 2 (see Section 2). 
yielded a 2 kbp fragment which was cloned into the 
EcoRV site of PBS. The DNA sequence of this fragment 
revealed the structure depicted in Fig. 1 and the partial 
sequence shown in Fig. 2. The only segment in the 
sequence between exons IIIa and 111~ which had typical 
Ig-domain features was found 1 kbp downstream of 
exon IIIa and is shown in Fig. 2. The sequence contains 
an open reading frame for 50 amino acids flanked by 
acceptor and donor splice sites in the correct orienta- 
tion. It contains the sequence DXGXYXC which is typ- 
ical for an Ig-domain near the second cysteine residue 
and this DNA segment may therefore be a candidate for 
exon IIIb of FGFR3. 
To determine whether the newly identified exon (IIIb) 
represents an authentic sequence of a new variant of 
FGFR3, we carried out PCR on cDNA prepared from 
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Fig. I. Genomlc btructure of the murme FGFR.1 domain III. (A) 
Physical map of the rxons encoding domain III The map was derived 
from DNA sequence of the 3 kbp fragment described m the text The 
transmembrane encoded Even TM (broken lmel IS shown to illustrate 
the posltion of oligonucleotlde 4. Numbered arrows show the posltion 
of ohgonucleotldea used for PCR (see Se&on 2). (B) Partial sequence 
of the 2 kb genomlc fragment showmg the sequence of exon IIIb and 
the exon_mtronJunctlons of exons IIIa. IIIb and 111~. DNA sequence 
of the exons 15 shown In capitals. Deduced ammo acids are shown in 
a smgle-letter code. 
RNA derived from mouse epidermal keratinocytes, 
using primers upstream and downstream (oligo 1 and 
oligo 4 in Fig. 1) to the putative new open reading 
frame. These primers where chosen so that only ampli- 
fication of authentic cDNA would yield fragments of 
the expected size while amplification of genomic DNA 
(a possible contaminant of the RNA preparation) 
would yield fragments containing intronic sequences. A 
420 bp DNA fragment was obtained as expected from 
the sites of the primers. This product was then used as 
a template for PCR using a primer specific for the new 
exon (oligo 5 in Fig. 1) and a second primer derived 
from the N-terminal half of Ig domain III and encoded 
by exon IlIa in FGFR3 (oligo 1 in Fig. 1) giving rise to 
a 400 bp DNA fragment (Fig. 2A, lane 1). Using two 
primers within exon IIIb (oligos 3 and 5 in Fig. 1). the 
only noticeable product was a 200 bp fragment as ex- 
pected from exon IIIb (Fig. 2A, lane 2). As a control, 
oligos 6 and 7 (Fig. I), specific to exon IIIC, were used 
giving a 154 bp fragment (Fig. 2A, lane 3). Further- 
more, the 400 bp product and the tentative exon IIIb 
PCR products, but not exon 111~ derived product, hy- 
bridized with exon IIIb specific probe (Fig. 2B, lanes 1, 
2 and 3, respectively). A DNA probe containing a large 
fragment of the authentic FGFR3 hybridized to both 
the 400 bp product and to exon 111~ but not to exon IIIb 
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(Fig. 2C, lanes 1, 3 and 2, respectively). Hybridization 
with exon 111~ specific probe gave a single positive band 
with exon 111~ derived PCR product only (Fig. 2D. lane 
3). These results clearly demonstrate that the identified 
new exon, IIIb. encodes an alternative carboxy terminal 
half of Ig-domain III of FGFR3. PCR analysis with 
exon IIIb specific primers gave a positive signal as de- 
termined by Southern blot when performed on cDNA 
derived from a 17.5-day mouse embryo and an adult 
mouse skin but not on cDNA derived from an undiffer- 
entiated teratocarcinoma cell line (data not shown). 
Subcloning and sequence analysis of the amplified 0.4 
kb fragment (Fig. 2, lane 1) confirmed its identity as an 
authentic novel cDNA of FGFR3 as well as the pre- 
dicted exon-intron borders (Fig. 1B). 
4. DISCUSSION 
The ligand-binding site of FGFRs was localized pre- 
viously to Ig domains 2 and 3 [3-5,191. Each of these 
domains is encoded by two exons, one for the N-termi- 
nal half (IIIa) and the other for the C-terminal half 
[3.1 I,1 51. The C-terminal half of Ig-domain 3, contain- 
ing approximately 50 amino acids, may be encoded by 
either of the two alternative exons IIIb or 111~. We and 
others have shown previously that this confined varia- 
ble region confers ligand specificity on FGFR2 [ 1 l- 131 
and that the ligand binding site of FGFRs is confined 
to Ig-domains 2 and 3 [19]. A similar arrangement of 
alternative exons was also described for FGFRl [13] 
but not for FGFR4 [14]. In this report we provide evi- 
dence that FGFR3 also contains two alternative exons 
for the C-terminal half of Ig-domain 3 similar to 
FGFRl and FGFR2. We searched for exon IIIb of 
FGFR3 by sequencing the entire DNA between exons 
IIIa and 111~ and we have identified a segment with 
Ig-domain characters flanked by consensus splice sites. 
A B C D 
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Fig. 2. PCR of exon IIIb and 111~ of FGFR3. cDNA derived from 
keratmocyte-RNA was used for PCR followed by gel electrophorests 
and Southern blot. Ohgonucleotides 1 and 5 (lane 1). 3 and 5 (lane 2) 
and 6 and 7 (lane 3) were used to amphfy different mouse ker- 
atmocytes cDNA. (A) PCR-amplified products as seen by ethidium- 
bromide. (B) Southern-blot of (A) hybridized with exon IIIb specific 
probe. (C) Southern blot of (A) hybridized wtth EtoRI fragment 
(780-2880 bp) of FGFR3. (D) Southern blot of (A) hybrtdized with 
exon 111~ specific probe. 
Fig 3. Comparison of the ammo acid sequences of exon IIIb of 
FGFR3. (A) Comparison of IlIb and 111~ from FGFR3. (B) Compar- 
ison of IIIb from various FGF receptors. Asterisks Indicate the com- 
mon Ig sequence DXGXYXC. Amino acids are given in the single- 
letter code. 
Furthermore. we demonstrated that this sequences is 
expressed in mouse tissues. The candidate for exon IIIb 
showed an open reading frame of 50 codons flanked by 
acceptor and donor splice sites at the 5’ and 3’ respec- 
tively (Fig. 1). In Fig. 3 we compare the amino acid 
sequences of the known exons IIIb from FGFR 1.2 and 
3. It is shown that whereas the sequence of IIIb from 
FGFRl and 2 are highly homologous, the sequence of 
IIIb from FGFR3 is markedly different from that of 
FGFRl and 2. Exon IIIb confers upon FGFR2 high 
affinity binding of KGF [ 11.121. The sequence dissimi- 
larity between exons IIIb and 111~ from FGFR3 (Fig. 
3) suggests that exon IIIb may also confer on FGFR3, 
a different ligand binding specificity. It is however not 
very likely that this will endow FGFR3 with KGF bind- 
ing because of the marked differences between the se- 
quence of IIIb reported here and that of KGFR ([ 11,121. 
Fig. 3). In the case of FGFR2 it has been shown that 
the alternative use of exons IIIb and 111~ is mutually 
exclusive in several cell lines [12]. Furthermore, the use 
of exon-specific probes of either IIIb or 111~ of FGFR2 
for in situ hybridization demonstrated that the tissue 
localization of the two FGFR2 variants differs mark- 
edly [20]. Alternative splicing between these two exons 
in FGFRs may therefore increase receptor diversity, 
determine differential tissue expression, and allow cells 
to respond selectively to environmental changes such as 
changes in available FGF ligands. Such a response may 
be important in developmental processes. pathological 
disorders or tumorigenesis. The analysis of these phe- 
nomena with FGFR3 variants described here may help 
further our understanding of the receptor-ligand rela- 
tionship in this complex family. 
Aclinoi~ledgenzmts: This work was supported by grants from The 
Council for Tobacco Research USA. the Israel Academy of Science. 
Ministry of Health. the USA-Israel Binattonal Science Foundatton. 
Mmerva Foundatton, the ICRF and the Baltmer Fund. We wash to 
thank Dr. Sabine Werner for helpful dtscusston and for sharmg with 
us mformatlon prtor to pubhcation. Mark Bedford for the RNA 
samples and San Levi for her contribution at the uuttal stage of the 
work. 
251 
Volume 330, number 3 FEBS LETTERS September 1993 
REFERENCES 
[I] Burgess. W.H. and Mactag, T. (1989) Annu. Rev. Biochem. 58, 
515 -606. 
[2] Basthco. C. and Moscatelh. D. (1992) Adv. Cancer Res. 59, 
115-165. 
[3] Gwol, D. and Yayon, A. (1992) FASEB J. 6. 336223369. 
[4] Jaye. M., Schlessinger. J. and Dtonne. C.A. (1992) Biochtm. Bio- 
phys. Acta 1135. 1855192. 
[5] Johnson. D.E. and Wtlhams. L.T. (1993) Adv. Cancer Res 60. 
141. 
[6] Crumley, G.. Bellot. F.. Kaplow, J.M., Schlessinger, J., Jaye, M. 
and Dianne. C.A (1991) Oncogene 6. 225552262. 
[7] Reid, H.H . Wilks. A.F. and Bernard, 0. (1990) Proc. Nat1 Acad. 
Sci. USA 87, 156991600 
[8] Johnson. D.E.. Lee, P.L.. Lee, J. and Williams. L.T. (1990) Mol. 
Cell Btol. IO. 472884736. 
[9] Katoh. M.. Hattort. Y., Sasakt. H.. Tanaka, M , Sugano. K.. 
Yazaki, Y.. Sugtmura, T. and Terada. M. (1992) Proc. Natl. 
Acad. SC]. USA 89, 2960-2964. 
[lo] Champion-Arnaud. P.. Ronsm, C., Gilbert, E.. Gesnel, M.C., 
Houssamt. E. and Breathnach. R. (1991) Oncogene 6. 9799987. 
[l l] Yayon, A., Ztmmer, Y, Hong, S.G., Avivi. A.. Yarden, Y. and 
Givol, D (1992) EMBO J. 11, 188551890. 
[12] Mtkt, T., Bottaro. D.P.. Fleming. T.P.. Smith, C L., Burgess, 
W.H.. Cham, A.M.-L and Aaronson, S.A. (1992) Proc. Nat). 
Acad. Sci. USA 89, 246250. 
[13] Werner. S., Duan, D.-A.R.. De Vrtes. C . Peters, K.G.. Johnson, 
D.E. and Williams. L.T. (1992) Mol. Cell. Btol. 12. 82-88. 
[14] Vaimkka, S.. Partanen. J . Bellosta. P, Coulier. F., Basthco, C., 
Jayer, M. and Alitalo, K ( 1992) EMBO J 11, 42734280 
[15] Johnson, D.E.. Lu, J , Chen, H.. Werner. S. and Williams. L.T. 
(1991) Mol. Cell. Biol. 11. 46274634 
[16] Avtvt. A., Ztmmer. Y.. Yayon, A . Yarden, Y. and Givol. D. 
(1991) Oncogene 6. 1089~1092. 
[17] Ornitz. D. and Leder P (1992) J. Biol. Chem. 267. 16305-16311. 
[18] Cathala. G . Savourent. J.F., Mendez, B.. West, B.L.. Karin. M., 
Marital, J A. and Baxter, J D. (1983) DNA 2. 329-335 
[19] Ztmmer. Y., Givol. D. and Yayon. A. ( 1993) J. Biol. Chem. 268, 
789997903. 
[20] Orr-Urtreger. A.. Bedford. M.T. Burakova. T, Arman. E.. Ztm- 
mer, Y., Yayon. A., Gwol, D and Lonat, P. (1993) Dev. Biol. (in 
press). 
252 
